PPD Acquires Acurian
Pharmaceutical Product Development has acquired patient-recruitment contractor Acurian.
Pharmaceutical Product Development (PPD), has acquired Acurian, a service provider of clinical trial patient enrollment and retention solutions for the life sciences industry.
Providing analytics-driven services to large and mid-sized pharmaceutical companies, Acurian manages the patient recruitment, enrollment, and retention. The company uses software analytics to customize approaches for recruiting patients for a customer’s clinical trial.
Acurian will continue to operate under its own name as a separate business unit with its existing management team led by Rick Malcolm, who has served as Acurian’s CEO since 2005.
Source:
Pharmaceutical Product Development
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
